Viatris Inc. Common Stock (VTRS) Financial Statements
Historical financial data — 27 statements covering FY2020–FY2025
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that...
Viatris Inc. Common Stock's revenue decreased 3.0% year over year, from $14.74B to $14.30B.
Net income decreased 454.2% over the same period, from $-634.2M to $-3.51B.
Over the 5-year period from FY2020 to FY2025, revenue grew by 20% in total.
Total debt decreased by 11.1% to $12.48B.
The debt-to-equity ratio stands at 0.85, indicating a moderate leverage profile.
Operating cash flow grew 0.6% to $2.32B.
Viatris Inc. Common Stock maintains a negative net profit margin of -24.6%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $3.75B-1.2% | $94.8M | $1.37B | $-587.1M | $826.5M | $44.75B | $14.30B | $19.79B |
| Q4 FY2024 | $3.53B-5.9% | $-516.5M | $1.22B | $-179.8M | $482.7M | $41.50B | $14.04B | $18.64B |
| Q1 FY2025 | $3.25B-7.8% | $-3.04B | $1.16B | $-2.88B | $535.5M | $38.47B | $14.18B | $15.65B |
| Q2 FY2025 | $3.58B+10.1% | $-4.6M | $1.33B | $233.0M | $219.7M | $38.41B | $12.79B | $15.57B |
| Q3 FY2025 | $3.76B+5.0% | $-128.2M | $1.37B | $178.8M | $744.9M | $37.92B | $12.49B | $15.22B |
| Q4 FY2025 | $3.70B-1.5% | $-340.1M | $1.15B | $-192.7M | $815.8M | $37.19B | $12.48B | $14.71B |
| Q1 FY2026 | $3.52B-5.0% | $176.4M | $1.16B | $-79.7M | $388.3M | N/A | N/A | N/A |
| Q2 FY2026 | $3.76B+6.8% | $-118.8M | $1.46B | $6.3M | $381.8M | N/A | N/A | N/A |
Balance Sheet Summary (FY2025)
Viatris Inc. Common Stock (VTRS) Financial Statements & Revenue History
Viatris Inc. Common Stock (VTRS) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry trading at $18.59 with a market capitalization of $21. This page provides 27 historical financial statements for Viatris Inc. Common Stock, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Viatris Inc. Common Stock reported revenue of $14.3 billion, a 3.0% decline from the prior year. The net profit margin of -24.6% indicates the company is currently unprofitable. The debt-to-equity ratio of 0.85 reflects moderate leverage.
VTRS Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Viatris Inc. Common Stock's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether VTRS is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track VTRS's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Viatris Inc. Common Stock converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of VTRS's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use VTRS Financial Data
Investors use Viatris Inc. Common Stock's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare VTRS's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how VTRS's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View VTRS's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Viatris Inc. Common Stock's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.VTRS trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.